Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
McIntyre Partnerships Chris McIntyre | “After a previously discussed successful trade in 2024, MDRX again became a top-five position following a failed sales process in Q1 2025. I believe the path forward is relatively straightforward: finish the audits, relist the shares in 2026, and then look to return cash to shareholders and/or sell the company if the market does not properly value it. MDRX is presently $4 with $1/sh. in net cash, $1/sh. in other investments, and should generate $0.50-$0.70/sh. in adjusted FCF in a normal year. In a deal with a strategic buyer, I believe $120MM in synergies, or 20% of sales, could be achieved, adding another $1/sh. in FCF. While the SaaS index trades at ~4-5x EV/Sales, MDRX trades at ~0.7x EV/Sales. I believe EHRs will be among the least affected software segments by AI. When relisted, I believe shares will trade at 15x normalized FCF, yielding $7-$11 versus $4.50 today. BSD Analysis: Veradigm is currently navigating a period of significant operational and legal headwinds, with its 2026 outlook clouded by a forecast decline in revenue and earnings. The company, formerly known as Allscripts, is struggling to regain its footing following accounting discrepancies and a subsequent delisting from major exchanges. Management has issued preliminary unaudited guidance that reflects the ongoing challenges in its core healthcare data and analytics business, with a focus on a 250 million dollar equity buyback to stabilize the share price. While some value-oriented analysts suggest the stock may be trading below its intrinsic value, the lack of audited financials and the threat of class-action litigation make it a high-risk proposition. The central question for 2026 is whether Veradigm can complete its financial reporting and prove the durability of its data-driven clinical solutions to restore investor trust.” | BULL | Q4 2025 Feb 19, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
